C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients-Reference-Cited by-同舟云学术

C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients

Published:2022-07-29 Issue:10 Volume:61 Page:1240-1247
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Kankkunen Elisa¹²,Penttilä Patrick¹²,Peltola Katriina¹,Bono Petri¹³

Affiliation:

1. Department of Oncology, Helsinki University Hospital, Helsinki, Finland

2. Department of Urology, Helsinki University Hospital, Helsinki, Finland

3. Terveystalo Finland and University of Helsinki, Helsinki, Finland

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2022.2104132

Reference34 articles.

1. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials

2. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer

3. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

4. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

5. PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

2. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis;Immunotherapy;2024-08-19

3. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report;Journal of Pharmaceutical Health Care and Sciences;2024-05-31

4. Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring;Cancers;2023-10-11

5. Supratentorial Collision Tumor of Hemangioblastoma and Metastatic Clear Cell Renal Cell Carcinoma in a Patient with von Hippel-Lindau Disease;Case Reports in Oncology;2023-09-18